Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308181805> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4308181805 endingPage "1381" @default.
- W4308181805 startingPage "1367" @default.
- W4308181805 abstract "Migalastat is approved for the treatment of Fabry disease (FD) with amenable variants. Objectives were to characterize effects of estimated glomerular filtration rate (eGFR) on oral clearance (CL), predict doses in mild to moderate renal impairment and in pediatric patients with FD, and to improve designs of FD studies. A 2-compartment model was fit to data from 260 subjects with/without FD and iteratively refined with evolving data. FD, eGFR, and weight affected CL, while weight and FD affected volume. Optimal sampling theory was used to choose pharmacokinetic sampling times for pediatric studies. Doses in patients with renal impairment and in pediatrics were determined by targeting exposure in adults receiving migalastat 123 mg every other day. A clinical study was conducted in 20 adolescent patients with FD ≥45 kg. eGFR had the largest effect on CL. Simulations showed that exposures in moderate renal impairment were within phase 2-3 exposures; patients aged 2-17 years require weight-based dosing; and predicted exposures in adolescent patients ≥45 kg receiving migalastat 123 mg every other day were similar to adults (data confirmed in a clinical study). Model-informed drug development optimized dosing and design of clinical studies and supported that no dose adjustments were needed in patients with mild to moderate renal impairment or in adolescent patients ≥45 kg." @default.
- W4308181805 created "2022-11-08" @default.
- W4308181805 creator A5000044132 @default.
- W4308181805 creator A5033423082 @default.
- W4308181805 creator A5038667880 @default.
- W4308181805 creator A5040528725 @default.
- W4308181805 creator A5050638714 @default.
- W4308181805 creator A5070117385 @default.
- W4308181805 date "2022-11-04" @default.
- W4308181805 modified "2023-10-17" @default.
- W4308181805 title "Population Pharmacokinetics of Oral Migalastat in Adolescents and Adults With and Without Renal Impairment" @default.
- W4308181805 cites W1550111394 @default.
- W4308181805 cites W1556650974 @default.
- W4308181805 cites W1602695946 @default.
- W4308181805 cites W1968678821 @default.
- W4308181805 cites W1997752174 @default.
- W4308181805 cites W2055558708 @default.
- W4308181805 cites W2063291039 @default.
- W4308181805 cites W2073742622 @default.
- W4308181805 cites W2077731206 @default.
- W4308181805 cites W2138506456 @default.
- W4308181805 cites W2155965977 @default.
- W4308181805 cites W2171238253 @default.
- W4308181805 cites W2189870152 @default.
- W4308181805 cites W2500404244 @default.
- W4308181805 cites W2523056550 @default.
- W4308181805 cites W2551668015 @default.
- W4308181805 cites W2963032744 @default.
- W4308181805 cites W2982699010 @default.
- W4308181805 cites W3049003068 @default.
- W4308181805 cites W3081163622 @default.
- W4308181805 cites W4211146209 @default.
- W4308181805 doi "https://doi.org/10.1002/cpdd.1160" @default.
- W4308181805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36331497" @default.
- W4308181805 hasPublicationYear "2022" @default.
- W4308181805 type Work @default.
- W4308181805 citedByCount "0" @default.
- W4308181805 crossrefType "journal-article" @default.
- W4308181805 hasAuthorship W4308181805A5000044132 @default.
- W4308181805 hasAuthorship W4308181805A5033423082 @default.
- W4308181805 hasAuthorship W4308181805A5038667880 @default.
- W4308181805 hasAuthorship W4308181805A5040528725 @default.
- W4308181805 hasAuthorship W4308181805A5050638714 @default.
- W4308181805 hasAuthorship W4308181805A5070117385 @default.
- W4308181805 hasBestOaLocation W43081818051 @default.
- W4308181805 hasConcept C112705442 @default.
- W4308181805 hasConcept C126322002 @default.
- W4308181805 hasConcept C126894567 @default.
- W4308181805 hasConcept C159641895 @default.
- W4308181805 hasConcept C187212893 @default.
- W4308181805 hasConcept C2777288759 @default.
- W4308181805 hasConcept C2908647359 @default.
- W4308181805 hasConcept C71924100 @default.
- W4308181805 hasConcept C99454951 @default.
- W4308181805 hasConceptScore W4308181805C112705442 @default.
- W4308181805 hasConceptScore W4308181805C126322002 @default.
- W4308181805 hasConceptScore W4308181805C126894567 @default.
- W4308181805 hasConceptScore W4308181805C159641895 @default.
- W4308181805 hasConceptScore W4308181805C187212893 @default.
- W4308181805 hasConceptScore W4308181805C2777288759 @default.
- W4308181805 hasConceptScore W4308181805C2908647359 @default.
- W4308181805 hasConceptScore W4308181805C71924100 @default.
- W4308181805 hasConceptScore W4308181805C99454951 @default.
- W4308181805 hasIssue "12" @default.
- W4308181805 hasLocation W43081818051 @default.
- W4308181805 hasLocation W43081818052 @default.
- W4308181805 hasOpenAccess W4308181805 @default.
- W4308181805 hasPrimaryLocation W43081818051 @default.
- W4308181805 hasRelatedWork W1973741567 @default.
- W4308181805 hasRelatedWork W2010711991 @default.
- W4308181805 hasRelatedWork W2039736044 @default.
- W4308181805 hasRelatedWork W2064815289 @default.
- W4308181805 hasRelatedWork W2067628361 @default.
- W4308181805 hasRelatedWork W2093874596 @default.
- W4308181805 hasRelatedWork W2994250685 @default.
- W4308181805 hasRelatedWork W3117263584 @default.
- W4308181805 hasRelatedWork W4296385806 @default.
- W4308181805 hasRelatedWork W4380738392 @default.
- W4308181805 hasVolume "11" @default.
- W4308181805 isParatext "false" @default.
- W4308181805 isRetracted "false" @default.
- W4308181805 workType "article" @default.